PrognomiQ Secures $34 Million Funding to Enhance Early Lung Cancer Detection with Multi-Omics Technology

Funding Amount:
PrognomiQ has secured $34 million in a series D funding round to advance its early lung cancer detection test.

Purpose:
The funding will be used to develop a blood-based early detection test for lung cancer, leveraging AI and proteomics to improve outcomes.

Technology:
The company's multi-omics technology combines various data types to enhance the detection and early treatment selection and monitoring of cancer.

Product Pipeline:
PrognomiQ aims to advance its multi-omics product pipeline for early detection and treatment of cancer with this funding.

Previous Financing:
The company had previously announced a $46 million financing to support its broader product development efforts.